Navigation Links
New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen

100% of Insulin Doses Administered Were Delivered Within Pre-Determined

Guidelines and Standard Dosing Limitations

BRIDGEWATER, N.J., May 5 /PRNewswire-FirstCall/ -- A new study examining the dose accuracy of the SoloSTAR(R) disposable insulin pen, prefilled with Lantus(R) (insulin glargine [rDNA origin] injection) or Apidra(R) (insulin glulisine [rDNA origin] injection), found the pens accurately delivered all insulin doses within standard limits defined by the International Organization for Standardization (ISO). Lantus(R) SoloSTAR(R) was approved by the U.S. Food and Drug Administration (FDA) on April 25, 2007. Apidra(R) for use in the SoloSTAR(R) prefilled disposable pen is currently under review at the FDA. The study, presented on May 2, 2008 at the 43rd Congress of the German Society for Diabetes (DDG) in Munich, Germany, examined the accuracy of both pens at multiple target dosages to determine the proportion of doses that fell within ISO ranges.

"For people with diabetes who use an insulin pen to deliver their insulin, dose accuracy is essential for their treatment," stated Norbert Hermanns, Ph.D., director of the Research Institute of the Diabetes Academy Mergentheim, Bad Mergentheim, Germany, and lead investigator in the study. "Based on the findings of this study, we concluded that the SoloSTAR(R) pen is an accurate insulin delivery option for people with diabetes."

The study participants, a random sample of 60 hospital inpatients with type 1 and type 2 diabetes, were trained on correct use of the SoloSTAR(R) pen. Participants were then asked to inject three target doses with Lantus(R) into an insulin-sponge, in doses of 10 (low), 40 (medium) and 80 (high) units, and three doses of Apidra(R) in doses of 5 (low), 15 (medium) and 30 (high) units. The quantity of insulin delivered was calculated by the weight of the insulin pens before and after injection. The order of the dosages was randomized. All doses (100%) were within the limits prescribed by the ISO standard (mean doses were only 0.9% to 1.3% below targets for Lantus(R), and 0.4% to 1.1% below targets for Apidra(R)), and the data set was within the ISO-defined 97.5% confidence intervals at each dose.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed. At the same time, approximately half of those diagnosed are not achieving the general blood sugar control standard of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over a two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

U.S. Contacts:

Carrie Melia



SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
4. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... BOSTON, Mass. (PRWEB) , ... November 26, 2015 ... ... a thorough second medical opinion process, participated in the 61st annual Employee Benefits ... Benefit Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
Breaking Medicine News(10 mins):